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Abstract
Background: Repeated antimalarial treatment for febrile episodes and self-treatment are common in malaria-endemic areas.
The intake of antimalarials prior to participating in an in vivo study may alter treatment outcome and affect the
interpretation of both efficacy and safety outcomes. We report the findings from baseline plasma sampling of malaria
patients prior to inclusion into an in vivo study in Tanzania and discuss the implications of residual concentrations of
antimalarials in this setting.
Methods and Findings: In an in vivo study conducted in a rural area of Tanzania in 2008, baseline plasma samples from
patients reporting no antimalarial intake within the last 28 days were screened for the presence of 14 antimalarials (parent
drugs or metabolites) using liquid chromatography-tandem mass spectrometry. Among the 148 patients enrolled, 110
(74.3%) had at least one antimalarial in their plasma: 80 (54.1%) had lumefantrine above the lower limit of calibration
(LLC = 4 ng/mL), 7 (4.7%) desbutyl-lumefantrine (4 ng/mL), 77 (52.0%) sulfadoxine (0.5 ng/mL), 15 (10.1%) pyrimethamine
(0.5 ng/mL), 16 (10.8%) quinine (2.5 ng/mL) and none chloroquine (2.5 ng/mL).
Conclusions: The proportion of patients with detectable antimalarial drug levels prior to enrollment into the study is
worrying. Indeed artemether–lumefantrine was supposed to be available only at government health facilities. Although
sulfadoxine–pyrimethamine is only recommended for intermittent preventive treatment in pregnancy (IPTp), it was still
widely used in public and private health facilities and sold in drug shops. Self-reporting of previous drug intake is unreliable
and thus screening for the presence of antimalarial drug levels should be considered in future in vivo studies to allow for
accurate assessment of treatment outcome. Furthermore, persisting sub-therapeutic drug levels of antimalarials in a
population could promote the spread of drug resistance. The knowledge on drug pressure in a given population is
important to monitor standard treatment policy implementation.
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Introduction
The intake of antimalarial drugs prior to inclusion in an in vivo
study may interfere with the estimation of treatment outcomes
(for both efficacy and safety) due to the presence of residual
antimalarials. The standard World Health Organization (WHO)
protocol for monitoring antimalarial drug efficacy does not
exclude patients with a history of previous antimalarial drug use
or the presence of antimalarial drugs in the urine or blood [1].
Nonetheless, it is customary in clinical studies to record the
occurrence of previous drug intake at screening as reported by the
patient, parent or guardian. Two studies in Africa investigated self-
reporting of drug intake [2,3], and both concluded that it is
inaccurate. A more objective indication on the drug use in a study
population would be obtained by screening the urine or blood
for the presence of antimalarial drugs. There are studies on
residuals of antimalarials that have been used in past policies, i.e.
chloroquine (CQ) or sulfadoxine–pyrimethamine (SP), in urine or
blood in the general population or patients [4–17]. However, to
our knowledge, there is no study on the presence of lumefantrine
in malaria patients seeking medical care.
Policy makers in malaria endemic countries are faced with the
difficult problem of ensuring easy and early access to effective and
high quality antimalarials, while preventing their uncontrolled and
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unnecessary use, which would increase drug pressure on the
parasites and encourage parasite resistance. Thus, knowledge of
drug use in a specific area could help decisions makers to assess
how treatment policies are implemented.
Here we report the findings of the analysis of baseline samples
from patients with Plasmodium falciparum malaria recruited in an in
vivo study in Tanzania. Samples were analysed for the presence of
14 currently in-use antimalarials in a single run using a liquid
chromatography-tandem mass spectrometry assay [18].
Methods
Ethics Statement
All the applied protocols and related documents were approved
by the Ethikkommission beider Basel (EKBB), the Institutional
Review Board of the Ifakara Health Institute and the National
Institute for Medical Research Review Board. Blood samples were
obtained after written informed consent in Swahili from the
participants or their responsible guardians.
Study Area and Population
The study was performed in a rural area with moderate to high
malaria transmission intensity (Kilombero district, Morogoro
region, Tanzania) during the main rainy season from March to
May 2008. At the time of the study, artemether–lumefantrine (AL)
had recently been introduced as first-line treatment and was only
available at government health facilities to ensure controlled
prescription. Before 2006, the official first-line treatment in
Tanzania was SP, which had in turn replaced CQ in 2001. In
2008, amodiaquine, SP and quinine were widely available in the
private sector in the study area. Artesunate, dihydroartemisinin,
and halofantrine could also be found sporadically in a few drug
shops (Alba S et al., in preparation). In the private sector these
drugs could be purchased over the counter without a doctor’s
prescription.
Febrile patients were recruited at the Kibaoni Health Center,
6 km from Ifakara down town, that serves a population of 26,261.
The population lives in villages with good coverage of government
health facilities and licensed drug stores (pharmacies, part II drug
stores [duka la dawa baridi] and Accredited Drug Dispensing Outlets
[ADDO; duka la dawa muhimu]) [19,20]. A map of the villages of
residence of the patients included in the study with location of
health facilities and drug dispensing outlets is presented in Figure 1.
Clinical Procedures
The trial was designed to assess the effects of the individual
pharmacogenetic profiles on the disposition of standard antima-
larials (to be reported elsewhere). It was based on the standard
WHO protocol for in vivo testing. Suspected malaria cases were
screened by rapid diagnostic test (Paracheck PfH, Orchid
Biomedical Systems, India) for the presence of Plasmodium
falciparum. Parasite count and specification of Plasmodium were
done by microscopy. The patients with a positive result were then
seen by a clinical officer, who invited them to participate in the
study if they did not present with danger signs of complicated
malaria or severe concomitant illness, and if they reported not
having taken antimalarials in the previous 28 days. The latter
information was checked against the patient’s care log book when
available. Consenting patients had a baseline sample (Day 0,
4.5 mL venous blood collected in an EDTA VacutainerH; Becton,
Dickinson and Company, USA) taken to check for potential
residual antimalarials and correct pharmacokinetic analyses later
on. Treatment with the standard first-line treatment AL was then
initiated, according to body weight and age category.
Laboratory Procedures
Blood samples were kept on ice for no longer than 6 h after bleeding
(venipuncture) and then aliquoted into whole blood, plasma and pellet
and immediately stored at 280uC. Plasma concentrations of 14
antimalarial drugs and their metabolites, i.e. artemether, artesu-
nate, dihydroartemisinin, amodiaquine, N-desethyl-amodiaquine,
lumefantrine, desbutyl-lumefantrine, piperaquine, pyronaridine,
mefloquine, chloroquine, quinine, pyrimethamine and sulfadox-
ine, were determined by liquid chromatography coupled to
tandem triple stage mass spectrometry (LC-MS/MS) [18]. The
lower limits of the calibration range (LLC) in our method were
selected as the lowest levels of the calibration curves, which
confidently provide a bias and CV% below 620%, in accordance
to FDA recommendations [21]. All samples were analyzed twice.
First, quantitative measurement was performed using calibration
and quality control samples; then, for confirmation, qualitative
assessment was repeated using a new chromatographic column
that had not been exposed to any antimalarial drugs,. In order to
exclude contamination and false positive results, a large set of
blank controls was analyzed prior to the clinical samples on the
new column, checking for the absence of specific MS/MS signals
of the antimalarials investigated.
Data Management and Analysis
Summary statistics, Chi-square tests, multivariate analysis and
graphs of residual plasma concentrations of antimalarials found prior
to treatment were produced using StataH (version 10.1 ‘‘inter-
cooled’’, Stata Corporation, College Station, TX, USA). Logistic
regression analysis was used to investigate the influence of body
weight, sex and distance from health facilities or pharmacies on the
presence of antimalarials at study entry. The distance between
patient home and health facility or pharmacy was defined as ‘‘close’’
or ‘‘far’’ depending on the distance in kilometers, also taking into
account ease of access, i.e. main road and river (according to
Figure 1). In the first multivariate analysis we considered Bondeni,
Kapolo, Katrini, Kibaoni, Kibaoni HC, Kikwawila, Kilolelo,
Kining’ina, Machipi, Maendeleo, Makelo, Mbasa, Mchonjoi,
Michenga C, Milola S, Muungano, Nakafulu, Sakamaganga B,
Station, and Viwanja Stini as ‘‘close’’ and Lungongole, Kilama A,
and Kilama B as ‘‘far’’. In the second analysis we also classified
Kilolelo, Kining’ina, Machipi, Makelo, and Michenga C as ‘‘far’’
because the flooding of the Lumemo river might have been an
obstacle during the rainy season. We also evaluated the contribution
of SP alone, AL alone or both, using likelihood ratio tests.
Estimation of Time of Drug Intake for Lumefantrine
To estimate the probable timing of drug intake, we compared
the plasma concentrations of lumefantrine at baseline (C0) and on
Day 7 (C7) after a complete treatment with AL for the same
patients. We included only patients for whom we had both samples
and who complied with the three-day, six-dose AL treatment
schedule. Assuming a terminal elimination half-life of tK=3.3
days for lumefantrine, an inter-individual variability of 40% [22]
and a similar dosage on pre-study exposure and during the study, a
back-calculation was done to estimate the intake time before
baseline sampling:
intake time~ln C7=C0ð Þ:t1=2

ln 2ð Þz7 days½ 
The variability on tK was used to estimate a 90% confidence
interval around this intake time, considering plausible inter-
individual variations in elimination rate [22].
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Bayesian Back-Calculations for Sulfadoxine
A Bayesian estimation of the most likely drug intake time was
also attempted from individual sulfadoxine plasma concentration
data, with a minimization approach using the ‘‘Solver’’ imple-
mented in Microsoft ExcelH. Patients were assumed to have taken
a single dose of sulfadoxine (combined with pyrimethamine)
according to body weight: 1500 mg for .45 kg, 1000 mg for 31–
45 kg, 750 mg for 21–30 kg, 500 mg for 11–20 kg and 250 mg for
5–10 kg. Approximate averages of pharmacokinetic parameters,
inter-individual variability and intra-individual (residual) variabil-
ity were derived from a literature review (Tables 1 and 2). These
parameters were used to back-calculate the most likely time for
dose intake, expected to produce the observed concentration
according to a standard one-compartment model. The variability
was used to estimate a 90% confidence interval around this intake
time, considering plausible variations in clearance, distribution
volume and measurement/modeling error [23]. Similar calcula-
tions were not attempted for other antimalarials, as their dosage
forms are more heterogeneous (lumefantrine and quinine), their
population pharmacokinetic parameters are less well characterized
(lumefantrine) and their half-lives are shorter (pyrimethamine,
quinine).
Results
A total of 1672 patients of all age were screened, of whom 389
(23%) had a positive malaria test and 150 were eligible and willing
to participate in the in vivo study. Two patients (one from the
Kibaoni HC area and one from Kining’ina) were excluded from
the analyses (venipuncture unfeasible in one patient; treatment
initiated before baseline sampling in the other one), leaving 148
patients with a valid baseline sample, of whom 64 (43.2%) were
male and 84 (56.8%) female (3 (2.0%) pregnant in 3rd trimester).
Patients’ ages ranged from 1 to 78 years (median 9 years). 51
(34.5%) patients were children under the age of 5, and 94 (63.5%)
were ,12 years old.
The presence of antimalarial drug was detected in the plasma of
111 (74.3%) patients: 80 (54.1%) had lumefantrine above the lower
limit of calibration (LLC=4 ng/mL), 7 (4.7%) desbutyl-lumefan-
trine (LLC=4 ng/mL), 77 (52.0%) sulfadoxine (LLC=0.5 ng/mL),
Figure 1. Villages of residence of the patients included in the study.
doi:10.1371/journal.pone.0008184.g001
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15 (10.1%) pyrimethamine (LLC=0.5 ng/mL), 16 (10.8%) quinine
(LLC=2.5 ng/mL) and none chloroquine (LLC=2.5 ng/mL) or
any other antimalarials tested. Summary statistics are shown in
Table 3, and box plots of residual plasma concentrations are
represented in Figure 2. Among the 111 patients with residual drug
concentrations, 57 (38.5%) hadmore than one drug (note that parent
drug and metabolite or combined regimens such as SP are
considered as one): 43 (29.1%) had both lumefantrine and SP, 6
(4.1%) had both lumefantrine and quinine, 1 (0.7%) had both SP
and quinine, and 7 (4.7%) had all three agents. The presence of
residual antimalarials in plasma was significantly more frequent
among children under 5 years of age (86.3%, x2= 5.82, P=0.016)
than among older children and adults (68.0% altogether).
For lumefantrine, among the 59 eligible patients the median
plasma concentration (range) was 18.3 ng/mL (4.4–181.8 ng/mL)
on Day 0 and 413 ng/mL (37.3–1402 ng/mL) on Day 7. This
means that, to account for the levels observed on Day 0, a similar
dosage level should have been administered at a median of 21 days
(interquartile range 17–24 days, whole range 11–29 days) before
study entry. In 2 patients (3%) this estimate was .28 days. The
variability in tK translates into 90% confidence intervals extending
from 74% to 144% of estimates (median).
Back-estimation of the most likely times for sulfadoxine intake
indicated a median of 108 days before blood sampling at study
entry (interquartile range 67 to 121 days, whole range ,1 to 130
days). Two patients had concentrations .78 mg/mL, compatible
with same day intake. In 70 patients (91%), the estimate exceeded
28 days. The evaluation of uncertainty around individual dose
intake times showed 90% confidence intervals extending from
49% to 202% of estimates (median).
The investigation of the influence of body weight, sex and
distance to health facilities or pharmacies on the probability of
residual antimalarials at study entry (details not presented) showed
only a significant relationship between body weight and residual
AL levels (likelihood ratio x2 = 9.06, P=0.03 in the first analysis;
likelihood ratio x2 = 9.60, P=0.02 in the second analysis), patients
with lower body weight being more likely to show residual AL
levels. However, this was not the case for SP or SP and AL taken
together. Furthermore, neither sex nor distance from health
facilities or pharmacies showed a significant effect on residual
levels of SP, AL or both at study entry.
Discussion
This is the first study investigating the presence of a range of
antimalarials in the plasma of African malaria patients on
enrollment into an in vivo study. The measurement of 14
antimalarial drugs currently in-use allowed a comprehensive
assessment of drugs available in the community under study.
Artemether–Lumefantrine
Three in four patients had detectable plasma concentrations of
antimalarials at the time of enrolment into the study, and in a
majority of cases the agent detected was lumefantrine/desethyl-
lumefantrine – indicating that they had taken AL, which was
supposedly available only at government health facilities to ensure
controlled prescription of first-line treatments. Assuming that the
patients had taken a three-day, six-dose AL treatment regimen,
Figure 2. Residual plasma concentrations of antimalarials found prior to treatment in 148 malaria patients. Number of patients (n),
median, 25th and 75th percentile, lower and upper adjacent values, and outside values are shown for lumefantrine, desbutyl-lumefantrine,
sulfadoxine, pyrimethamine and quinine on a logarithmic scale [ng/mL].
doi:10.1371/journal.pone.0008184.g002
Table 3. Residual plasma concentrations of antimalarials
found prior to treatment in 148 malaria patients [ng/mL].
Antimalarial Patients (%) Mean Median Minimum Maximum
Lumefantrine 80 (54.1) 25.3 15.8 4.4 181.8
Desbutyl-
lumefantrine
7 (4.7) 7.3 5.9 4.8 12.2
Sulfadoxine 77 (52.0) 49480.2 4.4 0.6 1389887.5
Pyrimethamine 15 (10.1) 56.8 7.1 0.9 391.3
Quinine 16 (10.8) 318.0 26.3 4.4 29947.2
No artemether, artesunate, dihydroartemisinin, amodiaquine, N-desethyl-
amodiaquine, piperaquine, pyronaridine, mefloquine, or chloroquine was
found.
doi:10.1371/journal.pone.0008184.t003
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most patients (97%) must have taken the drug within 28 days prior
to treatment. Furthermore, it is also possible that patients might
have taken a sub-therapeutic dose of AL more recently. However,
as indicated by the wide variability in elimination half-lives, these
values represent only rough estimates. Nevertheless, these findings
suggest that at least half of the patients included into our study had
taken AL, mostly within the previous month (one month
corresponds roughly to the limit of evaluation of past exposure,
considering assay LLC for lumefantrine). The Day 7 values
observed in this study are comparable with those of a study in Thai
patients [median plasma concentration (range) of lumefantrine was
528 ng/mL (49–5175 ng/mL) after 6 doses of AL over 60 h
according to body weight [24]] and in patients from Bangladesh
[860.3 ng/mL (53.8–6215.0 ng/mL) [25]]. Due to the short
half-life of the artemisinin component, e.g. 45 min for dihydroar-
temisinin, it is likely that none of the patients had taken a co-
formulated ACT (e.g AL) within the last 24 hours [26].
Sulfadoxine–Pyrimethamine
SP was still found in approximately half of the patients, although
it had been officially abandoned as first-line treatment since 2006.
Assuming that the patients with residual SP in their plasma had
taken a single dose of sulfadoxine according to body weight, most
patients must have taken the drug ,3.5 months (median 108 days)
prior blood withdrawal. However, 2 patients had sulfadoxine
plasma concentrations indicating very recent exposure, and
another 8 exposure during the last 4 weeks. Furthermore, it is
also possible that patients might have taken a sub-therapeutic dose
of SP more recently. These estimates are approximate, as
indicated by the wide confidence interval explained by the fair
degree of inter-individual variability in clearance, volume of
distribution and residual error. The LC-MS/MS method used for
the determination of sulfadoxine (LLC=0.5 ng/mL) would
theoretically make it possible to detect traces of sulfadoxine up
to 4 months (127 days) after a single dose of 25 mg/kg of
sulfadoxine. These findings are sufficient to conclude that a
significant number of patients had taken SP for a previous febrile
episode, which is against the standard treatment recommenda-
tions. Recent surveys on availability of antimalarials have shown
that sick people were getting SP from drugs shops, public and
private health facilities (Alba S et al., in preparation), especially so
when clinicians were doubtful about the diagnosis of malaria.
Chloroquine and Quinine
This study tends to confirm that CQ, replaced by SP as first-line
treatment in 2001, has been effectively withdrawn. On the other
hand, one tenth of the patients were found with quinine in their
plasma. Quinine has an elimination half-life of 16–18 h in malaria
patients [27]. After a treatment with 10 mg/kg of quinine
dihydrochloride administered 8-hourly orally for 7 days, the
plasma quinine levels had fallen to below 0.4 mg/mL in almost all
patients 40 h after the last dose on Day 7 [28]. Thus, we infer that
most patients with quinine levels in our study must have taken the
last quinine dose not more than 2 days before reporting at the
health facility.
High Numbers of Patients with Residual Antimalarials
Why was the number of patients with residual antimalarials so
high? Through the demographic surveillance system (DSS) data
and a treatment seeking survey in the Ifakara area it was found
that approximately 8% of children had fever in the previous 2
weeks when seen between January and April 2008 (Alba S et al.,
personal communication). An epidemiological study which used
the Explanatory Model Interview Catalogue (EMIC) reported that
87.5% (78.2–93.8%) of all fevers in children in our study area were
treated with one of the recommended antimalarials (at that time
SP, amodiaquine or quinine) [13]. Based on these data, one would
expect 14% of children to have had an antimalarial treatment in
the preceding month (i.e. (0.0862)60.875), which is much lower
than the proportion of patients with residual antimalarial plasma
levels in this study (86.3% for under 5 s, 68% for older children
and adults). This large discrepancy could be either due to poor
recall of the study subjects in the epidemiological survey or a
selection bias. The latter could have arisen either because we
captured (i) only patients preferentially seeking antimalarial
treatment at a health facility instead at drug shops (,76.3% of
children under the age of 5 years receiving treatment according to
the epidemiological study), (ii) patients who are more susceptible to
repeated infections (and hence repeated treatments) or are more
exposed to infection, or (iii) patients with easy access to treatment.
However, similar results were found in two study sites in rural
Cambodia (Hodel et al., in preparation).
Reliability of Medical History
Whatever the reason is for the large number of malaria patients
with antimalarials in their blood at study baseline, the fact remains
that these patients are the usual subjects investigated in in vivo
studies and clinical trials. All patients included in the study
reported not having taken antimalarials in the previous 28 days.
Entry criteria based on self-reporting of previous drug intake (poor
recall) or information recorded in the care log book (self-treatment
not documented) are thus unreliable at least in this population and
for lumefantrine.
Potential Bias in Drug Safety and Efficacy Assessment
Previous drug intake may affect the current treatment in several
ways. Higher drug exposure resulting from cumulative levels may
lead to better efficacy or more toxicity. The parasites causing the
disease at the time of enrolment may be of a less sensitive population
selected by the previous treatment. Thus, previous antimalarial intake
may impact on the outcome of the treatment under investigation, and
this study shows that only baseline drug concentration measurement
in the blood can reliably be used to account for this effect. Our LC-
MS/MS assay covers 14 antimalarials in a single run. We can
confidently exclude a lack of specificity and false positives as we
included blank plasma samples as negative controls and systemati-
cally repeated the measurement on a new chromatographic column.
Furthermore, we have demonstrated that all drugs are stable for up to
48 h in plasma stored at 4uC [18]. Therefore, even in settings, where
no LC-MS/MS instrument is available, samples can be collected in
the field, and easily kept and transported to the nearest laboratory
where they can be frozen and stored until assayed or further shipped
to their final destination. The identification of patients with residual
antimalarials allows distinguishing pre-treated from untreated
subjects in a secondary analysis. This distinction should probably
not aim at excluding pre-treated patients from enrollment in efficacy
studies, but rather at addressing the question wether residual
antimalarials affect subsequent treatment or not. Detractors may
point out that the distinction between pre-treated and untreated
patients (i) does not reflect clinical reality and (ii) will increase the
number of participants required to maintain statistical power. We
believe it could be an important information if some safety or efficacy
issues arise from the observations.
High Drug Pressure as Risk Factor for the Spread of Drug
Resistance
There is abundant literature on the effects of inadequate
antimalarial treatment on the emergence and spread of resistance.
Antimalarial Use in Tanzania
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8184
Here, we do not know if the residual drug levels found were from a
full or incomplete treatment, if the person had parasites at the time
of the previous drug intake, and whether the parasites causing the
current episode are the same or a new infection. Be it as it may,
the residual levels were not enough to control parasite replication
and clinical symptoms. This means that these parasites have been
exposed to inadequate drug levels for some time. The chances of
drug resistant parasites to be selected depends on several factors,
and is higher for patients with no immunity (e.g. young children),
drugs with long residence times and resistance being conferred
through single point mutations, and for infections with a large
parasite biomass [29]. These patients had a mean baseline para-
site biomass of,961010 (ranging from,16108 to,661011, data
not shown), values which are in line with those reported for
symptomatic cases in malaria-endemic areas [30], and were
exposed to drug concentrations which were likely to be in the
selective window [31].
The findings of this study must be confirmed in other settings as
they have potential implications for both clinical research and
surveillance (treatment efficacy and safety outcome) and control
(pharmaco-epidemiology, adherence to policy).
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